Cart
sales@molnova.com
LTGO-33
CAS No. 2834106-06-6
LTGO-33( —— )
Catalog No. M37510 CAS No. 2834106-06-6
LTGO-33 is a species-specific inhibitor of the voltage-gated sodium channel NaV1.8, inhibiting NaV1.8, NaV1.1-NaV1.7, and NaV1.9.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 151 | In Stock |
|
| 5MG | 147 | In Stock |
|
| 10MG | 221 | In Stock |
|
| 25MG | 404 | In Stock |
|
| 50MG | 594 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLTGO-33
-
NoteResearch use only, not for human use.
-
Brief DescriptionLTGO-33 is a species-specific inhibitor of the voltage-gated sodium channel NaV1.8, inhibiting NaV1.8, NaV1.1-NaV1.7, and NaV1.9.
-
DescriptionLTGO-33 is a species-specific inhibitor of the voltage-gated sodium channel NaV1.8, inhibiting NaV1.8, NaV1.1-NaV1.7, and NaV1.9.LTGO-33 inhibits wild-type and multiple NaV1.8 variants associated with human pain disorders and can be used for the study of pain.hBChE-IN-2 is a low affinity Nurr1 agonist.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetSodium Channel
-
RecptorSodium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2834106-06-6
-
Formula Weight467.44
-
Molecular FormulaC21H17F4N3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[S@@](C1=CC=CC(NC(C2=C(N=CC(C(F)(F)F)=C2)OC3=C(C=C(C=C3)F)C)=O)=C1)(=N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Oxcarbazepine
Oxcarbazepine is structurally a derivative of carbamazepine, adding an extra oxygen atom to the benzylcarboxamide group.
-
Bupivacaine
Bupivacaine (AH-250) is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.
-
Zandatrigine
Zandatrigine (NBI-921352) is a sodium channel protein type 8 subunit alpha blocker, suitable for studies on epilepsy treatment and nervous system pathologies.
